February 12, 2009 — Ustekinumab significantly reduces signs and symptoms of psoriatic arthritis and diminishes skin lesions in patients with active psoriatic arthritis, including those with psoriasis affecting 3% or more body surface area, according to results of a phase 2, double-blind, randomized, placebo-controlled, crossover study published online today in The Lancet. The drug was well tolerated, with a similar incidence of adverse events and infections compared with placebo up to week 12 (the double-blind portion of the study).
It is a laboratory-manufactured monoclonal antibody directed against interleukins IL-12 and IL-23.
No comments:
Post a Comment
Please add your comments or suggestions here..
Note: Only a member of this blog may post a comment.